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ABSTRACT
Introduction: Patients with rheumatoid
arthritis (RA) have decreased survival because
of increased cardiovascular risk compared with
the general population, and treatment with
tocilizumab (TCZ) has been shown to increase
lipid levels; however, the relationship between
lipids and cardiovascular risk is unknown. This
post hoc analysis expanded on previously
reported 24-week results by characterizing
statin use and subsequent changes in lipid
parameters in patients with RA treated with
intravenous or subcutaneous TCZ (TCZ-IV or
TCZ-SC) over 2 years of treatment.
Methods: Data were collected from patients
with moderate to severe active RA who
received C1 dose of the study drug in seven
international, randomized, double-blind,
controlled phase 3 and 4 clinical trials of
TCZ-IV or TCZ-SC. Lipid levels and safety
events were assessed over 2 years of treatment.
Data were summarized for all pooled treatment
groups of the intention-to-treat populations in
the TCZ-IV and TCZ-SC studies, and results were
stratified by concomitant statin use.
Results: Data from this descriptive,
retrospective, pooled analysis indicated that
statins can stabilize lipid levels without a
clinically significant increase in adverse events.
Approximately 30% of patients in the TCZ
treatment arms who never received a statin
demonstrated a shift in low-density-lipoprotein
cholesterol (LDL-C) from \130 mg/dl at
baseline to C130 mg/dl at 2 years. However,
despite the increased potential cardiovascular
risk,\15% of patients with LDL-C C100 mg/dl
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and \35% of patients with a total
cholesterol:high-density-lipoprotein cholesterol
ratio [5 at 2 years were receiving concomitant
statins.
Conclusion: Concomitant statin use attenuated
TCZ-mediated lipid increases; however, a large
proportion of TCZ-treated patients potentially
at risk of cardiovascular disease were untreated.
These findings highlight the need for better
understanding of potential risk associated with
TCZ-mediated lipid elevations as well as
implementation of RA-specific guidelines on
the recognition and management of elevated
risk of cardiovascular events in patients with
RA.
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INTRODUCTION
Rheumatoid arthritis (RA) is a disease
characterized by chronic inflammation and is
associated with decreased survival compared
with the general population [1]. This excess
mortality in patients with RA is largely due to
an increased risk of cardiovascular (CV) disease,
although it remains unclear whether chronic
inflammation, altered lipid levels, and/or
traditional risk factors are the main drivers of
the increased risk of CV events observed in RA
[2–4]. In patients with RA, lipid levels appear to
have a paradoxical relationship with CV disease
risk [5–8]. Whereas elevated lipid levels are
typically associated with an increased risk of CV
disease in the general population, lower lipid
levels appear to be associated with an increased
risk of CV disease in patients with RA [5].
Evidence suggests that reductions in
time-averaged disease activity may decrease the
risk of CV events [9]; reductions in C-reactive
protein in patients with RA may lead to
improvements in high-density-lipoprotein
cholesterol (HDL-C) efflux and increases in
apolipoprotein AI, which may counteract any
potential elevated CV risk because of concurrent
increases in low-density-lipoprotein cholesterol
(LDL-C) [10]. In addition, treatment with
different classes of disease-modifying
antirheumatic drugs (DMARDs) has
demonstrated different directional changes in
levels of lipid parameters and risk of CV disease;
however, associations between
treatment-induced alterations in lipid profiles
and CV outcomes are unknown. For example, in
patients with RA, treatment with tumor necrosis
factor inhibitors has been shown to significantly
increase HDL-C, total cholesterol (TC), and
triglyceride (TG) levels without altering LDL-C
levels, while treatment with the interleukin 6
receptor a inhibitor tocilizumab (TCZ) generally
increases levels of all four of these parameters
[11]. Another study found that treatment with
tumor necrosis factor inhibitors was associated
with decreased risk of CV events compared with
conventional synthetic DMARD (csDMARD) use,
but lipid levels were not assessed [12].
TCZ, a humanized monoclonal antibody
that inhibits interleukin 6 receptor a, is
approved as monotherapy or in combination
with methotrexate for the treatment of patients
with moderate to severe RA who have had an
inadequate response to C1 csDMARD. TCZ has
proven to be safe and efficacious when used in
combination with csDMARDs or as
monotherapy [13–20]. Several clinical trials
have investigated the effects of intravenous
TCZ (TCZ-IV) or subcutaneous TCZ (TCZ-SC)
therapy on lipid levels in patients with RA and
Rheumatol Ther
generally found elevations in TC, LDL-C,
HDL-C, and TGs by &12–16 weeks in patients
treated with TCZ, which remained stable over
time (Table S1) [13, 15–30]. In addition, an
integrated safety report from five randomized
controlled trials and their long-term extension
studies (AMBITION, RADIATE, TOWARD,
OPTION, LITHE) demonstrated that lipid levels
were elevated in the TCZ all-exposed
population as early as 6 weeks after the first
TCZ infusion and remained at these levels
throughout 104 weeks of treatment [31].
Another retrospective analysis examined the
associations of baseline and on-treatment lipid
levels, inflammation, and disease activity with
risk of major adverse CV events in TCZ-treated
patients pooled from five randomized
controlled trials and their extension studies.
This study found that changes in measures of
RA disease activity, but not necessarily changes
in lipids, were associated with an increased
incidence of major adverse CV events in
TCZ-treated patients [32]. Notably, TCZ doses
as high as 20 mg/kg had no impact on LDL-C
levels in healthy volunteers [33]. Whether these
lipid elevations actually increase or decrease the
risk of CV disease in TCZ-treated patients with
RA is unclear; however, patients may benefit
from treatment with lipid-lowering therapy,
such as statins.
The identification of potential statin-related
adverse events (AEs) was initially evaluated in
TCZ-treated patients who were or were not
treated with concomitant statins at baseline,
over 24 weeks using pooled data collected from
five phase-3 clinical trials of TCZ-IV in patients
diagnosed with moderate to severe RA
according to the 1987 American College of
Rheumatology classification criteria [34, 35].
Overall, treatment with TCZ plus csDMARDs or
as monotherapy resulted in increased mean
LDL-C levels. The initial magnitude of the
increase in mean LDL-C levels over the first
6 weeks was lower in TCZ-treated patients
treated with concomitant statins from baseline
than in the overall TCZ-treated population; the
initiation of statin treatment post-baseline
reduced mean LDL-C levels below baseline
values in TCZ-treated patients. The original
analysis included only studies of TCZ-IV.
TCZ-SC is now approved; therefore, it is also
important to evaluate TCZ-SC in patients with
RA, especially to assess whether management of
hyperlipidemia has evolved between the time of
the initial pivotal trials of TCZ-IV and the more
recent trial investigating TCZ-SC [18, 19]. The
objectives of this post hoc analysis were to
expand on the previous 24-week results by
characterizing statin use in patients with RA
who were treated with TCZ and to describe
subsequent changes in lipid parameters
stratified by concomitant baseline statin use,
using data from seven different international




In this post hoc analysis, data were collected
from patients who received C1 dose of study
drug in seven international, multicenter,
randomized, double-blind, controlled phase 3
and 4 clinical trials (OPTION, TOWARD,
AMBITION, LITHE, ADACTA, SUMMACTA,
RADIATE), which were designed to evaluate
the safety and efficacy of TCZ-IV or TCZ-SC in
patients with moderate to severe active RA
[13–17, 19, 20]. Data from the seven TCZ-IV
studies and the 24-week double-blind and
72-week open-label periods of SUMMACTA
were pooled into four treatment groups: (1)
Rheumatol Ther
csDMARD monotherapy, (2) TCZ-IV 8 mg/
kg q4w monotherapy, (3) TCZ-IV 8 mg/
kg q4w ? csDMARD combination therapy, and
(4) TCZ-SC 162 mg qw ? csDMARD
combination therapy in order to primarily
examine the effects of equi-effective TCZ doses
(TCZ-IV 8 mg/kg q4w and TCZ-SC 162 mg qw).
The data within each treatment group were
analyzed for patients who were on a statin at
baseline, initiated a statin post-baseline, or
never received a statin at any point during the
study.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the studies.
Clinical Assessments
Fasting lipid levels were assessed at baseline,
3–4, 6, 12 months, and 2 years; data were
summarized for all pooled treatment groups of
the intention-to-treat populations in the
TCZ-IV and TCZ-SC studies. Demographic
characteristics and inflammatory biomarker
levels—including C-reactive protein, serum
amyloid A, haptoglobin, and lipoprotein(a)—
were assessed at baseline. Notably, patients in
the TCZ-IV treatment arms were followed for up
to 5 years; however, due to the small numbers
of patients at these longer time points, only the
lipid level assessments from the first 2 years of
follow-up were included in this analysis.
Guidelines for initiation of lipid-lowering
therapy vary by study site locations; however,
the decision to start a statin or other
lipid-lowering drug was at the discretion of the
investigator and not mandated by the
individual study protocols (Table S2). For this
analysis, LDL-C C100 mg/dl or TC:HDL-C ratio
[5 was used as a crude predictor of CV risk. To
estimate whether statins were appropriately
given in at-risk patients, we calculated the
proportion of patients above each threshold
who were on statins at each visit.
Selected AEs that were chosen post hoc as
AEs that may, but not necessarily or causally, be
related to statin use were assessed for up to
5 years during the individual studies and
included musculoskeletal and connective
tissue disorders, arthralgia, musculoskeletal
pain, and myalgia. Serious CV events included
all preferred terms in the Medical Dictionary for
Regulatory Activities within the ‘‘cardiac
disorders’’ and ‘‘vascular disorders’’ system
organ classes.
Statistical Analysis
Descriptive statistics were used to summarize
laboratory data, statin use, and AEs at each visit,
and the results were stratified by concomitant
statin use. All laboratory data were converted to
the International System of Units and
summarized with actual values and with the
change from baseline over visits. Abnormal
laboratory values were classified according to
the National Cancer Institute’s Common
Terminology Criteria for Adverse Events
grading system (version 3) [36]. Shift
tables summarized the proportion of patients
at each visit with categorical shifts in lipid
parameters from normal values at baseline
(LDL-C \130 mg/dl; TC \240 mg/dl; HDL-C
\60 mg/dl; TG \150 mg/dl) to the highest
post-baseline values (LDL-C C130 mg/dl; TC
C240 mg/dl; HDL-C C60 mg/dl; TG C150 mg/
dl).
All selected AEs and serious CV events were
presented as event rates per 100 patient-years
Rheumatol Ther
with 95% confidence intervals. No statistical




In this post hoc analysis, statin use and lipid
levels were analyzed over time in 4655 patients
with RA pooled from the seven phase 3 and 4
TCZ-IV and TCZ-SC clinical trials [csDMARD
monotherapy (n = 1361), TCZ-IV 8 mg/kg q4w
monotherapy (n = 450), TCZ-IV 8 mg/kg
q4w ? csDMARD combination therapy
(n = 2213), TCZ-SC 162 mg qw (n = 631)].
Baseline demographic and clinical
characteristics for all patients pooled from the
seven phase 3 and 4 TCZ-IV and TCZ-SC clinical
trials stratified by baseline statin use are
presented in Table 1. Patients on statins at
baseline in the TCZ-IV and TCZ-SC studies
were generally older and weighed more
compared with patients not treated with
statins at baseline (Table 1). A higher
proportion of patients on statins at baseline
were male, had diabetes, had a family history of
coronary heart disease, and had a history of
hypertension and cardiac disorders compared
with patients who were not treated with statins
at baseline. These trends were similar in the
TCZ-IV and TCZ-SC treatment groups (Table 1).
Description of Statin Use Over Time
In this post hoc analysis of 4655 patients,
including 2616 patients (56.2%) with elevated
LDL-C levels C100 mg/dl at baseline, 443
patients (9.5%) were on concomitant statins at
baseline, 264 patients (5.9%) initiated statins
post-baseline, and 3948 patients (84.8%) never
initiated a statin during the study period.
Baseline statin use was comparable across all
treatment groups (range 8.0–11.4%) (Table S3).
The most common lipid-lowering agents used
at all time points were the lipophilic agents
simvastatin and atorvastatin, with 3.2–4.6% of
patients in each arm receiving simvastatin and
2.7–3.2% of patients receiving atorvastatin.
Over time, statin use generally increased in
the TCZ treatment groups and was three- to
fourfold higher at 2 years (range 13.8–17.4%)
compared with patients receiving csDMARD
monotherapy (4.5%).
Analysis of Lipid Parameters
Evolution of LDL-C Over Time by Statin Use
Statin use at baseline appeared to attenuate the
increase in LDL-C over time. Of patients who
were on a statin at baseline, mean (SD) LDL-C
levels ranged from 98.3 (34.6) to 101.9 (29.0)
mg/dl, with no clear differences across
treatment groups based on overlapping
confidence intervals (Fig. 1a). Of patients who
initiated a statin post-baseline, mean (SD)
LDL-C levels ranged from 129.1 (32.4) to 144.6
(42.6) mg/dl, with the lowest values observed in
the TCZ-IV monotherapy treatment group
(Fig. 1b). Patients who were untreated with
statins at any time point during the study had
baseline LDL-C levels in between those of
patients who were on statins at baseline and
those who initiated statins post-baseline, with
mean (SD) levels ranging from 109.1 (32.9) to
114.9 (33.5) mg/dl (Fig. 1c). Although LDL-C
levels at baseline were highest in patients who
initiated statins post-baseline, the magnitude of
the LDL-C increase over the first 3–4 months of
TCZ treatment was similar across treatment
groups. Evaluation of mean TC, HDL-C, and
TG levels over time for patients on statins at


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































and those untreated with statins at any time is
presented in the Supplemental Material
(Figs. S1–S3). The observed trends in TC,
HDL-C, and TG changes were generally similar
to those seen for LDL-C. Importantly, patients
who were on concomitant statins at baseline or
who never received statins during the study
period exhibited persistent elevations in lipids
after 3–4 months, whereas those patients who
initiated statins post-baseline demonstrated
gradual decreases in lipid levels over time,
signaling a possible trend toward
normalization of previously elevated lipids.
Lipid Shifts from Baseline to Last Observation
by Statin Use
Shifts in lipid parameters from normal values at
baseline to the highest post-baseline values over
time are presented for patients stratified by
statin use (Table 2). Of patients who were on
statins at baseline, 31.8% (7/22), 24.8% (34/
137), and 29.8% (14/47) of patients receiving
TCZ-IV as monotherapy, TCZ-IV plus
csDMARDs, or TCZ-SC, respectively,
demonstrated an increase in LDL-C from
























Patients On Statins at Baseline
csDMARD Monotherapy
TCZ-IV q4w Monotherapy
TCZ-IV q4w + csDMARD





TCZ-IV q4w + csDMARD











































Patients Initiating Statins Post-baseline
csDMARD Monotherapy
TCZ-IV q4w Monotherapy
TCZ-IV q4w + csDMARD





TCZ-IV q4w + csDMARD











































Patients Untreated With Statins at Any Point
csDMARD Monotherapy
TCZ-IV q4w Monotherapy
TCZ-IV q4w + csDMARD





TCZ-IV q4w + csDMARD





















Fig. 1 Mean LDL-C levels over time in patients who were
on statins at baseline (a), patients who initiated statins
post-baseline (b), and patients who were untreated with
statins at any time (c). csDMARD conventional synthetic
disease-modifying antirheumatic drug, IV intravenous,
LDL-C low-density-lipoprotein cholesterol, qw every week,












































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Similar trends were observed for TCZ-treated
patients who were untreated with statins at any
time; however, as expected, a higher proportion
of patients overall exhibited a shift from LDL-C
\130 mg/dl at baseline to LDL-C C130 mg/dl
(Table 2). Of those never treated with statins,
38.4% (81/211), 36.7% (408/1111), and 42.4%
(133/314) of patients receiving TCZ-IV as
monotherapy, TCZ-IV plus csDMARDs, or
TCZ-SC, respectively, demonstrated an
increase in LDL-C from\130 mg/dl at baseline
to C130 mg/dl at 3–4 months. These trends
were consistent through 2 years of
observation; however, the smaller numbers of
patients followed over time preclude making
any meaningful conclusions. Notably, a lower
proportion of patients who were randomized to
csDMARD monotherapy and were on statins at
baseline or who were never treated with statins
demonstrated a shift from LDL-C\130 mg/dl at
baseline to LDL-C C130 mg/dl at 3–4 months
compared with any TCZ therapy [13.6% (8/59)
and 12.9% (92/712), respectively].
Similar trends were generally observed for
categorical shifts in TC, HDL-C, and TGs by
treatment group and statin use (Table 2).
Compared with patients who were never
treated with statins, a smaller proportion of
TCZ-treated patients (any formulation) who
were on statins at baseline demonstrated shifts
in TC and HDL-C from normal values (\240 and
\60 mg/dl, respectively) at baseline to elevated
levels (C240 and C60 mg/dl, respectively)
through 6 months. This observation continued
through 2 years for all treatment groups, except
for the shift in TC in patients receiving TCZ-SC
at 12 months and shifts in HDL-C in patients
receiving TCZ-IV or TCZ-SC plus csDMARDs
(observed through 12 months). Compared with
patients who were never treated with statins, a
larger proportion of patients receiving TCZ (IV
or SC) plus csDMARDs demonstrated shifts in
TGs from\150 mg/dl at baseline to C150 mg/dl
through 2 years of follow-up. Statin use did not
appear to have an appreciable effect on shifts
from baseline in TC, HDL-C, or TGs for patients
randomized to csDMARD monotherapy.
Proportion of Patients Treated with Statins
by Elevated LDL-C Levels and TC:HDL-C Ratio
For this analysis, LDL-C C100 mg/dl was used to
define patients who should be treated with
lipid-lowering agents, regardless of whether
they were prescribed one or not. The
proportions of patients with LDL-C C100 mg/
dl at baseline who were treated with statins at
baseline, 3–4, 6, 12 months, and 2 years are
presented in Table 3. Overall, &60% of patients
across all studies had LDL-C C100 mg/dl at
baseline: only 6.3–7.1% of patients in the
TCZ-IV arms and 5.4% of patients in the
csDMARD treatment arms were treated with
statins. At 2 years, &78% of patients in the
TCZ-IV arms had LDL-C C100 mg/dl; of these
patients, only 11.0 and 13.3% of patients
receiving TCZ-IV as monotherapy and
combination therapy, respectively, were
treated with statins. A higher proportion of
TCZ-SC-treated patients with LDL C100 mg/dl
at baseline were treated with statins at baseline
(8.6%) than those in the TCZ-IV studies;
however, overall, a high proportion of patients
remained untreated. The proportion of patients
receiving TCZ-SC with LDL-C C100 mg/dl who
were also treated with statins generally
increased over time; however, only 13.6% of
patients were treated with statins despite having
LDL-C C100 mg/dl at 2 years.
Similarly, the proportion of patients with
TC:HDL-C [5 (above-average risk) who were
treated with statins at any time point was low
(Table 3). Approximately 5–10% of patients
across all treatment groups had TC:HDL-C [5













































































































































































































































































































































































































































































































































































































































































































































































































patients who were receiving TCZ-IV as
monotherapy or combination therapy,
respectively, were treated with statins. The
proportion of TCZ-SC-treated patients treated
with statins was only slightly higher (13.9%).
The proportion of patients with TC:HDL-C [5
generally increased over time across the studies,
accounting for &15–20% of TCZ-treated
patients at 2 years. Compared with patients
who had LDL-C C100 mg/dl, a higher
proportion of patients with TC:HDL-C[5 were
treated with statins at 2 years. Patients
randomized to TCZ-SC were the most likely to
be treated with statins (30.5%), followed by
TCZ-IV monotherapy (23.8%) and TCZ-IV plus
csDMARDs (16.0%). Higher statin use in
patients treated with TCZ-SC was an expected
finding, because it was already known from the
TCZ-IV studies that blood lipid concentrations
during TCZ treatment should be monitored and
treated, if needed.
Safety
The rates of selected AEs and serious CV events
by statin use are summarized in Table 4. Of
patients randomized to TCZ-IV 8 mg/kg
q4w ? csDMARDs, those who were on
concomitant statins at baseline had a higher
rate of C1 musculoskeletal and connective
tissue disorder, arthralgia, musculoskeletal
pain, and myalgia per 100 person-years
compared with patients in the same treatment
arm who never received a statin during the
study. For the TCZ-IV 8 mg/kg q4w
monotherapy and TCZ-SC 162 mg qw
treatment groups, similar rates of AEs
commonly associated with statin use were
observed across any of the statin groups. The
low numbers of patients in the non-TCZ arms
who were treated with concomitant statins
precluded any meaningful comparisons to
determine any effect of TCZ treatment on
these safety events. The overall rates of serious
cardiac disorders and vascular disorders were
low and similar between treatment groups or by
statin use.
DISCUSSION
This was a large, descriptive, post hoc analysis of
4655 patients enrolled in phase 3 and 4 TCZ
trials. Overall, &60% of patients had baseline
LDL-C levels C100 mg/dl, and 9.5% of patients
were on a concomitant statin at baseline.
Treatment with TCZ plus csDMARDs or as
monotherapy resulted in increased mean
LDL-C levels in patients with moderate to
severe RA, regardless of the route of
administration. The initial increases in mean
LDL-C levels over 3–4 months were comparable
across all treatment groups; however, patients
who initiated statins post-baseline experienced
a subsequent decrease in LDL-C levels over
time, whereas patients who were on statins at
baseline or who were never treated with statins
demonstrated a persistent elevation in LDL-C
after 3–4 months of treatment. Similar trends
were observed with TC, HDL-C, and TGs.
However, despite these results, we also found
that only a small proportion of patients who
may be at a higher risk of CV disease (as
estimated by LDL-C C100 mg/dl or TC:HDL-C
[5) were treated with statins at any time point.
Because this was a descriptive post hoc
analysis using pooled data, this study is not
without some limitations. Notably, because a
variety of different lipid-lowering agents were
used, and at varying doses, it is difficult to
ascertain the true effect of statins for the
treatment groups that received concomitant
statins at baseline or initiated statin treatment




















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































to discern whether hydrophilic statins (e.g.,
pravastatin and rosuvastatin) exhibit a different
effect on TCZ-mediated increases in lipids
compared with lipophilic statins (e.g.,
atorvastatin, lovastatin, simvastatin). There
was also a relatively small number of patients
with long-term lipid level assessments and
related outcomes (up to 5 years); therefore, the
lack of extended follow-up for larger numbers of
patients may preclude making any meaningful
conclusions about long-term trends in lipids
and associations with concomitant statin use.
However, a randomized, open-label,
parallel-group, multicenter study designed to
evaluate the rate of CV events over 5 years of
follow-up with TCZ in comparison to
etanercept in patients with RA was completed
earlier this year (ClinicalTrials.gov identifier
NCT01331837). Finally, the AEs assessed in
this study were selected on a post hoc basis to
describe events that may be related to statin use;
however, there is no evidence to confirm that
statin use had a causal relationship with any of
these events.
LDL-C levels should be monitored and
managed in patients with RA. Screening and
monitoring risk factors for CV disease are
important for preventative and management
strategies in high-risk populations. The most
widely used assessments of CV risk are the
Framingham Risk Score, the Systematic
Coronary Risk Evaluation, the Reynolds Risk
Score, and the QRisk2 score; however, these
algorithms were developed for the general
population and do not account for any
additional risk due to RA-specific risk factors.
Unfortunately, many current risk calculators
may underestimate CV disease risk in patients
with RA, indicating a need for an RA-specific
calculator to estimate risk of CV disease. A
prospective study from an early RA inception
cohort found that the Framingham Risk Score,
the Systematic Coronary Risk Evaluation, and
the Reynolds Risk Score primarily
underestimated CV risk at low and moderate
observed risk levels while mostly overestimating
CV risk at higher observed risk levels [37]. The
QRisk2 score generally overestimated CV risk at
all levels of observed CV risk. These results
highlight the need for development of an
RA-specific risk model to improve prediction
of CV risk in patients with RA and management
of traditional CV risk factors [37, 38]. A recent
systematic literature review to identify and
appraise all CV disease prevention guideline
recommendations and quality indicators
identified a total of ten guidelines that
provided recommendations for CV disease
prevention in patients with RA published
between 2008 and 2013 [39]. Of these, only
the European League Against Rheumatism
(EULAR) guidelines suggested a formal
adjustment of the CV risk score to account for
the presence of RA and recommended control
of RA disease activity as a potential means of
reducing CV disease risk in RA [40]. The
recommendations acknowledge that RA should
be regarded as a condition associated with
higher CV disease risk. One of the
recommendations notes that risk-score models
should be adapted for patients with RA by
introducing a 1.59 multiplication factor, and
this multiplication factor should be used when
patients with RA meet two of the following
three criteria: disease duration [10 years,
rheumatoid factor or anticyclic citrullinated
peptide antibody positivity, and/or presence of
certain extra-articular manifestations. Although
there are many guidelines and quality
indicators for CV risk assessment similar to the
EULAR recommendations, clear gaps exist in
clinical care, such as how antirheumatic
treatments modify CV risk, which should be
addressed by development of RA-specific
Rheumatol Ther
guidelines [39]. A newer, expanded risk score for
CV outcomes in patients with RA (ERS-RA) was
developed to improve upon existing prediction
models by incorporating RA-specific factors
(e.g., RA disease activity, disability, daily
prednisone use, and disease duration) in
addition to traditional risk factors, allowing for
more targeted management of CV disease in
patients with RA [41].
CONCLUSION
In conclusion, data from this pooled analysis
indicate that statins can stabilize lipid levels
without a clinically significant increase in AEs of
interest in patients treated with TCZ-IV or
TCZ-SC. Approximately 30% of patients in the
TCZ treatment arms who never initiated a statin
demonstrated a shift in LDL-C from\130 mg/dl
at baseline to C130 mg/dl at 2 years; however,
only a small proportion of patients with LDL-C
C100 mg/dl or TC:HDL-C[5 were treated with
statins at any point during the study. TCZ is
known to reduce chronic inflammation, and
these results suggest that concomitant treatment
with statins may attenuate lipid increases with
TCZ treatment. Taken together, these findings
highlight the need for better understanding of
potential risk associated with TCZ-mediated lipid
elevations as well as development and
implementation of RA-specific guidelines on
the recognition and management of elevated
risk of CV events in patients with RA.
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